Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1996 1
1997 1
2012 1
2013 1
2016 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

6 results
Results by year
Filters applied: . Clear all
Page 1
The potential clinical relevance of visible particles in parenteral drugs.
Doessegger L, Mahler HC, Szczesny P, Rockstroh H, Kallmeyer G, Langenkamp A, Herrmann J, Famulare J. Doessegger L, et al. Among authors: kallmeyer g. J Pharm Sci. 2012 Aug;101(8):2635-44. doi: 10.1002/jps.23217. Epub 2012 May 24. J Pharm Sci. 2012. PMID: 22628244 Review.
[Synthesis of polymer bound antiphlogistic agents].
Roth HJ, Kallmeyer G. Roth HJ, et al. Among authors: kallmeyer g. Arch Pharm (Weinheim). 1988 May;321(5):273-6. doi: 10.1002/ardp.19883210507. Arch Pharm (Weinheim). 1988. PMID: 3421817 German. No abstract available.
Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis.
Porteous DJ, Dorin JR, McLachlan G, Davidson-Smith H, Davidson H, Stevenson BJ, Carothers AD, Wallace WA, Moralee S, Hoenes C, Kallmeyer G, Michaelis U, Naujoks K, Ho LP, Samways JM, Imrie M, Greening AP, Innes JA. Porteous DJ, et al. Among authors: kallmeyer g. Gene Ther. 1997 Mar;4(3):210-8. doi: 10.1038/sj.gt.3300390. Gene Ther. 1997. PMID: 9135734 Clinical Trial.